Kidney cancer gets new drugs, competition

	Tweet

For the first time in decades there are new treatments available for kidney cancer, and as more data emerges about their efficacy, the competition looks set to heat up.

Data presented on Sunday at the annual meeting of the American Society of Clinical Oncology confirmed the potency of Sutent, a drug marketed by Pfizer Inc. that was approved by U.S. regulators in January.

For the first time, too, data was released from a late-stage, or phase III, clinical trial of an experimental new drug from Wyeth called temsirolimus that showed it improved overall survival by 49 percent in patients with the poorest outlook.

Nexavar, a drug made by Onyx Pharmaceuticals Inc. and Bayer AG, was approved in December and has already shown that it doubled the time before the disease progressed to 24 weeks from 12 weeks for patients in the placebo group.

On Monday, investigators will release updated survival data for Nexavar. This time last year, interim results of a phase III trial showed that Nexavar improved survival by 39 percent, but the results were not statistically significant.

While trial investigators for Sutent and temsirolimus each claimed superiority for their drug, they conceded that direct comparisons were impossible as each trial was designed differently. The Sutent trial, for example, tested patients with a wide range of disease severity, from those whose prognosis was favorable to those whose prognosis was poor. About 40 percent were in the middle.

The late-stage confirmatory trial of Sutent showed the median time before which a patient’s disease progressed was 11 months in the Sutent group compared to five months in the group taking standard interferon therapy. The response rate, a measure of tumor shrinkage, was 31 percent in the Sutent group compared to 6 percent in the interferon group.

The results did not show whether patients who took Sutent lived longer than those who took the standard therapy.

Wyeth, by contrast, only tested patients with the poorest prognosis. Its trial found patients who were treated with temsirolimus alone had a median survival time of 10.9 months, compared with 7.3 months in the interferon group.

“In general, in oncology, drugs that work in patients with the worst prognosis will work at least as well if not better in those with a better prognosis,” said Gary Hudes, director of the genitourinary malignancies program at Fox Chase Cancer Center in Philadelphia.

The Wyeth drug, which has not yet been approved, is important because it is the first to fully validate the potential of a new target for cancer therapy called mTOR, Hudes said. mTOR is a signaling protein that regulates cell and blood vessel growth.

RELATED STORIES:
Kidney Cancer Patients Unlikely to Respond to Potential Treatment Drug   New drug prolongs survival of advanced kidney cancer   Kidney removal does not prolong the lives of elderly patients with localized kidney cancer   How Less Can Be More When Treating Some Kidney Cancers   Researchers Find Genetic Secrets to Common Kidney Cancer   A tissue marker of poor prognosis in clear cell renal cell carcinoma   Percutaneous cryoablation is a safe method for treating kidney tumors   Women fare better than men, but need more blood after kidney cancer surgery   Diet can increase risk of kidney cancer   High bread consumption tied to kidney cancer   Eating fatty fish may ward off kidney cancer   Moderate drinking may lower kidney cancer risk   US approves new drug for advanced kidney cancer   Can kidney disease cause cancer?   2 drugs work better together than either alone against kidney cancer   Ablation proved as effective as traditional surgery in treating kidney cancer   Majority of kidney cancers diagnosed at earliest stage   Kidney Cancer Patients May Be Overtreated   Early childbirth, big family tied to kidney cancer   Folic acid may reduce some childhood cancers   Novel therapy for metastatic kidney cancer developed at VCU Massey Cancer Center   Lead blood levels may increase smokers’ risk for kidney cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]